HomeCompareVMTHF vs SBUX

VMTHF vs SBUX: Dividend Comparison 2026

VMTHF yields 474.05% · SBUX yields 2.84%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 VMTHF wins by $40759.94M in total portfolio value
10 years
VMTHF
VMTHF
● Live price
474.05%
Share price
$0.42
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$40760.11M
Annual income
$28,806,329,273.60
Full VMTHF calculator →
SBUX
SBUX
● Live price
2.84%
Share price
$86.72
Annual div
$2.46
5Y div CAGR
48.3%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$167.0K
Annual income
$71,136.45
Full SBUX calculator →

Portfolio growth — VMTHF vs SBUX

📍 VMTHF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodVMTHFSBUX
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, VMTHF + SBUX cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
VMTHF pays
SBUX pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

VMTHF
Annual income on $10K today (after 15% tax)
$40,293.91/yr
After 10yr DRIP, annual income (after tax)
$24,485,379,882.56/yr
SBUX
Annual income on $10K today (after 15% tax)
$241.12/yr
After 10yr DRIP, annual income (after tax)
$60,465.98/yr
At 15% tax rate, VMTHF beats the other by $24,485,319,416.58/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of VMTHF + SBUX for your $10,000?

VMTHF: 50%SBUX: 50%
100% SBUX50/50100% VMTHF
Portfolio after 10yr
$20380.14M
Annual income
$14,403,200,205.03/yr
Blended yield
70.67%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on SBUX right now

VMTHF
No analyst data
Altman Z
-0.0
Piotroski
3/9
SBUX
Analyst Ratings
28
Buy
27
Hold
3
Sell
Consensus: Buy
Price Target
$104.00
+19.9% upside vs current
Range: $90.00 — $120.00
Altman Z
2.6
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

VMTHF buys
0
SBUX buys
0
No recent congressional trades found for VMTHF or SBUX in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricVMTHFSBUX
Forward yield474.05%2.84%
Annual dividend / share$2.00$2.46
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%48.3%
Portfolio after 10y$40760.11M$167.0K
Annual income after 10y$28,806,329,273.60$71,136.45
Total dividends collected$39707.63M$136.4K
Payment frequencyquarterlyquarterly
SectorStockConsumer Discretionary

Year-by-year: VMTHF vs SBUX ($10,000, DRIP)

YearVMTHF PortfolioVMTHF Income/yrSBUX PortfolioSBUX Income/yrGap
1← crossover$58,105$47,404.60$11,121$420.68+$47.0KVMTHF
2$319,595$257,422.91$12,548$648.40+$307.0KVMTHF
3$1,665,249$1,323,282.78$14,440$1,013.98+$1.65MVMTHF
4$8,225,711$6,443,893.93$17,068$1,617.30+$8.21MVMTHF
5$38,549,580$29,748,069.43$20,912$2,649.52+$38.53MVMTHF
6$171,541,094$130,293,043.94$26,875$4,499.29+$171.51MVMTHF
7$725,407,583$541,858,612.30$36,771$8,014.12+$725.37MVMTHF
8$2,917,676,445$2,141,490,330.46$54,542$15,197.11+$2917.62MVMTHF
9$11,171,756,198$8,049,842,402.84$89,602$31,242.49+$11171.67MVMTHF
10$40,760,108,406$28,806,329,273.60$167,011$71,136.45+$40759.94MVMTHF

VMTHF vs SBUX: Complete Analysis 2026

VMTHFStock

Venus Medtech (Hangzhou) Inc. develops and commercializes transcatheter heart valve medical devices in Mainland China and internationally. The company's products include VenusA-Valve, a transcatheter aortic heart valve replacement (TAVR) product to treat severe aortic stenosis; VenusP-Valve is a transcatheter pulmonary valve system to treat the dysfunction of right ventricular outflow tract; V8/TAV8 balloon aortic valvuloplasty catheter systems; and TriGUARD3, a cerebral embolic protection device for minimizing the risk of brain damage and prevent cerebral embolism during TAVR and other structural heart disease surgeries. It also develops VenusA-Plus and VenusA-Pilot, which are TAVR product candidates; and transcatheter mitral and tricuspid valve replacement products; Liwen RF ablation system for the treatment of hypertrophic cardiomyopathy; and renal denervation for the treatment of hypertension. The company was founded in 2009 and is headquartered in Hangzhou, the People's Republic of China.

Full VMTHF Calculator →

SBUXConsumer Discretionary

Starbucks Corporation, together with its subsidiaries, operates as a roaster, marketer, and retailer of specialty coffee worldwide. The company operates through three segments: North America, International, and Channel Development. Its stores offer coffee and tea beverages, roasted whole beans and ground coffees, single serve products, and ready-to-drink beverages; and various food products, such as pastries, breakfast sandwiches, and lunch items. The company also licenses its trademarks through licensed stores, and grocery and foodservice accounts. The company offers its products under the Starbucks, Teavana, Seattle's Best Coffee, Evolution Fresh, Ethos, Starbucks Reserve, and Princi brands. As of October 3, 2021, it operated 16,826 company-operated and licensed stores in North America; and 17,007 company-operated and licensed stores internationally. The company was founded in 1971 and is based in Seattle, Washington.

Full SBUX Calculator →
📬

Get this VMTHF vs SBUX comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

VMTHF vs SCHDVMTHF vs JEPIVMTHF vs OVMTHF vs KOVMTHF vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.